Franck Touret Selected Research

COVID-19

1/2024	Neutralizing and Enhancing Monoclonal Antibodies in SARS-CoV-2 Convalescent Patients: Lessons from Early Variant Infection and Impact on Shaping Emerging Variants.
8/2023	Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases.
6/2023	Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model.
8/2022	Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19.
8/2022	Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2.
1/2022	Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
12/2021	A Bioluminescent 3CLPro Activity Assay to Monitor SARS-CoV-2 Replication and Identify Inhibitors.
1/2021	Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).
1/2021	Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
11/2020	Drugs against SARS-CoV-2: What do we know about their mode of action?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Franck Touret Research Topics

Disease

15	COVID-19 01/2024 - 01/2020
7	Infections 01/2024 - 09/2018
2	Virus Diseases (Viral Diseases) 01/2023 - 01/2020
2	Dengue (Dengue Fever) 01/2023 - 01/2019
1	Malaria 01/2023
1	Lung Injury 01/2023
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 08/2022
1	Lymphocytic Choriomeningitis 01/2022
1	Disease Progression 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Severe Acute Respiratory Syndrome 01/2020
1	Yellow Fever 09/2018
1	Breast Neoplasms (Breast Cancer) 01/2011
1	Neoplasms (Cancer) 01/2011

Drug/Important Bio-Agent (IBA)

12	Antiviral Agents (Antivirals)IBA 01/2023 - 01/2019
2	Monoclonal AntibodiesIBA 01/2024 - 06/2023
2	CytokinesIBA 01/2023 - 01/2021
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2022 - 01/2020
2	VaccinesIBA 01/2020 - 09/2018
1	AntibodiesIBA 01/2024
1	ensitrelvirIBA 01/2024
1	JNJ-1802IBA 01/2023
1	Phosphotransferases (Kinase)IBA 01/2023
1	Antimalarials (Antimalarial Agents)IBA 01/2023
1	Emodin (Archin)IBA 01/2023
1	nitazoxanide (NTZ)FDA Link 08/2022
1	ExoribonucleasesIBA 01/2022
1	Azithromycin (Zithromax)FDA LinkGeneric 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 12/2021
1	Firefly LuciferasesIBA 12/2021
1	(+)- 4- (3- ((1- (4- chlorophenyl)- 2- oxo2- (6- (trifluoromethoxy)indolin- 1- yl)ethyl)amino)- 5- methoxyphenoxy)butanoic acidIBA 10/2021
1	favipiravirIBA 01/2021
1	Imatinib Mesylate (Gleevec)FDA Link 01/2021
1	Niclosamide FDA Link 01/2021
1	Chloroquine (Aralen)FDA LinkGeneric 01/2020
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 01/2020
1	Detergents (Detergent)IBA 01/2020
1	Viral RNAIBA 01/2020
1	NucleosidesIBA 01/2020
1	BuffersIBA 01/2020
1	EnzymesIBA 01/2019
1	NITD008IBA 01/2019
1	Neutralizing AntibodiesIBA 09/2018
1	Proteins (Proteins, Gene)FDA Link 09/2018
1	Glycoproteins (Glycoprotein)IBA 01/2011
1	Biomarkers (Surrogate Marker)IBA 01/2011
1	Galectin 1 (LGALS1)IBA 01/2011
1	HaptoglobinsIBA 01/2011
1	Immunoglobulin M (IgM)IBA 01/2011

Therapy/Procedure

6	Therapeutics 08/2023 - 01/2020